[Skip to Content]
[Skip to Content Landing]
Views 257
Citations 0
Research Letter
January 18, 2017

A Novel Alternate Dosing of Vismodegib For Treatment of Patients With Advanced Basal Cell Carcinomas

Author Affiliations
  • 1Department of Dermatology, University of Minnesota, Minneapolis
JAMA Dermatol. Published online January 18, 2017. doi:10.1001/jamadermatol.2016.5058

Basal cell carcinoma (BCC) is the most common cutaneous malignancy with a favorable prognosis, as the estimated cure rate when treated early is around 95%.1 Despite this, BCC can progress locally or metastasize. Vismodegib has been shown to lead to significant improvement in patients with advanced BCC.2 Unfortunately, adverse effects (AE) have often led to drug discontinuation.2,3

First Page Preview View Large
First page PDF preview
First page PDF preview